Clinical Efficacy Observation of Yiqi Huoxue Prescription in Treating Coronary Heart Disease with Qi Deficiency and Blood Stasis Syndrome After PCI

Affiliated Hospital of Chengdu University of traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Subjects meeting the diagnostic criteria of ACS;
•2. Subjects aged 40 to 80 years;
•3. Subjects with successful percutaneous coronary intervention (complete revascularization of target vessel);
•4. Subjects with cardiac function I-III (NYHA classification);
•5. Subjects who meet the syndrome differentiation standard of qi deficiency and blood stasis syndrome of chest stuffiness and heartache;
•6. Subjects who signed informed consent and agreed to participate in the trial.

•1. Patients who need continuous mechanical adjuvant therapy after successful interventional therapy;
•2. Patients with severe liver, kidney, hematopoiesis, nervous system diseases, psychosis and malignant tumor;
•3. Pregnant or lactating women;
•4. Allergic constitution and patients with suspected or definite allergy to related drugs;
•5. Patients with persistent atrial fibrillation and fatal arrhythmia;
•6. Patients whose compliance is poor and the possibility of follow-up is poor;
•7. Patients who are participating in other clinical trials or in recent 3 months.

发起方

Affiliated Hospital of Chengdu University of traditional Chinese Medicine